Alpha-synuclein is a small protein concentrated at the tips of nerve cells, where it helps regulate the release of chemical signals between neurons. In Parkinson’s disease, this ordinarily useful protein misfolds, clumps together, and gradually destroys the very brain cells it was meant to serve. The discovery in 1997 that a mutation in the gene encoding alpha-synuclein could cause inherited Parkinson’s disease transformed the field, turning what had been a poorly understood condition into one with a clear molecular villain at its center. The story, though, is not as simple as “bad protein kills neurons.” How alpha-synuclein shifts from helper to threat, how that threat spreads through the brain, and whether it can be stopped are questions researchers are still working to answer.
What Alpha-Synuclein Does in a Healthy Brain
Alpha-synuclein is abundant at synapses, the junctions where one neuron communicates with the next. Under normal conditions, it binds to the membranes of tiny sacs called synaptic vesicles and plays a role in how neurotransmitters are packaged, released, and recycled. Exactly what that role looks like is still debated: some evidence points to the protein helping assemble the molecular machinery that fuses vesicles with the cell membrane, while other work suggests it acts as a brake on neurotransmitter release by limiting how many vesicles are available to fire at once.1PubMed Central. α-Synuclein in synaptic function and dysfunction Research has shown these two roles may not actually conflict: alpha-synuclein interacts with a vesicle protein called VAMP2, and that interaction both supports vesicle recycling and dampens release, depending on timing and demand.2PubMed Central. Functional cooperation of α-synuclein and VAMP2 in synaptic vesicle recycling
The protein is not limited to the brain. Alpha-synuclein appears in red blood cells, the gut’s own nervous system, and other tissues. This widespread distribution matters for both understanding the disease and, as discussed later, for diagnosis.
A Protein with a Shape-Shifting Problem
For years, alpha-synuclein was described as “natively unfolded,” meaning it floats around inside cells without a fixed three-dimensional shape. That changed when researchers isolated the protein under gentler laboratory conditions and found that it naturally forms a compact four-unit structure, roughly 58 kDa, that resists clumping.3PubMed Central. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation Follow-up work confirmed that even an engineered version of alpha-synuclein could form a stable four-unit cluster without needing to attach to a membrane first.4PubMed Central. A soluble α-synuclein construct forms a dynamic tetramer
This finding reframed the disease question. If the protein’s healthy state is a tidy, aggregation-resistant cluster, then anything that destabilizes that cluster, whether a genetic mutation, oxidative stress, or sheer overproduction, could push individual copies of alpha-synuclein toward misfolding. Once monomers start stacking into the wrong shape, the process can snowball.
Genetic Evidence That Too Much Alpha-Synuclein Is Enough
The gene that encodes alpha-synuclein is called SNCA. In 1997, researchers identified a point mutation in SNCA as the cause of autosomal dominant Parkinson’s disease in a large Italian-American family known as the Contursi kindred.5PubMed Central. The Identification of Alpha-Synuclein as the First Parkinson Disease Gene Since then, several other missense mutations in SNCA have been linked to inherited forms of the disease.
Perhaps more telling are the families in which the SNCA gene itself is duplicated or triplicated on one chromosome. People carrying a duplication, meaning three total copies instead of the normal two, develop Parkinson’s that looks clinically typical but often starts early and includes non-motor features like sleep disturbance, hallucinations, and cognitive decline.6PubMed Central. Autosomal dominant Parkinson’s disease caused by SNCA duplications Those carrying a triplication, four copies, get hit harder and faster: more severe dementia, more severe motor disability, and more frequent loss of bladder control despite similar disease duration.7JAMA Neurology. α-Synuclein Gene Rearrangements in Dominantly Inherited Parkinsonism: Frequency, Phenotype, and Mechanisms Disease severity tracks with how many copies of the gene are present, not with what other genes happen to lie nearby on the duplicated stretch of DNA.8PubMed Central. Genomic investigation of α-Synuclein multiplication and parkinsonism
The implication is straightforward: you do not need a mutant version of alpha-synuclein to cause Parkinson’s. Simply making too much of the normal protein is enough. That principle has driven much of the therapeutic research aimed at reducing alpha-synuclein levels.
Oligomers, Fibrils, and Lewy Bodies
When alpha-synuclein begins to misfold, it does not jump straight to the large tangles visible under a microscope. It first assembles into small clusters called oligomers. These oligomers can eventually stack into long, thread-like fibrils, which in turn aggregate with other cellular debris to form the dense deposits known as Lewy bodies, the hallmark pathological finding in Parkinson’s disease.
For decades, researchers assumed that the fibrils and Lewy bodies themselves were the main agents of damage. More recently, the focus has shifted to the smaller oligomers. In animal experiments, variants of alpha-synuclein engineered to favor oligomer formation caused more severe loss of dopamine-producing neurons than variants that quickly formed fibrils.9PubMed Central. In vivo demonstration that alpha-synuclein oligomers are toxic The emerging view is that oligomers, not mature fibrils, are the primary toxic species in Parkinson’s and related diseases.10PubMed Central. Toxic species in amyloid disorders: Oligomers or mature fibrils One reason may be structural: naturally forming oligomers contain more of a particular kind of folded sheet in their interior that appears to be critical for damaging cell membranes.11bioRxiv. Structure Specific Neuro-toxicity of α-Synuclein Oligomer
Lewy bodies themselves are more than just balls of alpha-synuclein. Detailed imaging has revealed that they trap mitochondria, fragments of the cell’s waste-disposal systems, and other organelles. The process of building a Lewy body, with its entanglement of misfolded protein and hijacked cellular machinery, may be a major driver of neurodegeneration in its own right.12PubMed Central. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration The sequestration of organelles inside Lewy bodies correlates more closely with neuron death than the amount of aggregated alpha-synuclein alone.13Science Translational Medicine. Beyond synuclein: Organelle accumulation in Lewy bodies may drive neurodegeneration
How Misfolded Alpha-Synuclein Spreads Through the Brain
One of the more unsettling discoveries of the past two decades is that misfolded alpha-synuclein appears to spread from neuron to neuron in a pattern resembling how prion diseases work. Misfolded seeds enter a healthy neuron, come into contact with normal alpha-synuclein already inside, and template those normal copies into the misfolded shape. The newly corrupted protein can then travel to the next connected neuron and repeat the cycle.14PubMed Central. Prion-like propagation of pathology in Parkinson disease This cell-to-cell spread follows the brain’s own wiring, which helps explain why Parkinson’s pathology appears in a predictable pattern, climbing from the brainstem into midbrain and eventually cortex over years or decades.15PubMed Central. The Prion-Like Spreading of Alpha-Synuclein in Parkinson’s Disease: Update on Models and Hypotheses
To be clear, alpha-synuclein is not a prion in the traditional infectious-disease sense. It does not appear to transmit between people through casual contact. The term “prion-like” refers strictly to the mechanism of conformational templating within a single person’s nervous system.16PubMed Central. Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like Propagation
The Gut-to-Brain Route
One especially active line of research asks whether the disease might start outside the brain entirely. Abnormal forms of alpha-synuclein have been found in the nerves of the gut before they show up in the brain.17PubMed Central. Parkinson’s disease from the gut In mouse experiments, injecting misfolded alpha-synuclein into the gut wall triggers a stepwise climb: within one month, phosphorylated alpha-synuclein appears in the brainstem. By three months, it reaches the amygdala and begins accumulating in the substantia nigra, the midbrain region whose dopamine neurons are devastated in Parkinson’s.18Neuron. Gut-to-Brain Propagation of Pathologic α-Synuclein via the Vagus Nerve Causes Parkinson’s Disease-like Phenotypes The highway for this spread appears to be the vagus nerve, the long nerve that connects the gut to the brainstem.19ACS Chemical Neuroscience. Comprehensive Review on Potential Signaling Pathways Involving the Transfer of α‑Synuclein from the Gut to the Brain That Leads to Parkinson’s Disease
Environmental factors, including pesticides and certain pathogens, have been proposed as triggers that could initiate alpha-synuclein misfolding in the gut’s nervous system. This “body-first” model of Parkinson’s disease does not account for every patient; some clearly develop pathology in the brain first. But it has prompted major interest in whether early gut-related symptoms like constipation, which often precede motor symptoms by years, could serve as a warning sign.
Damage at the Cellular Level
Inside an affected neuron, misfolded alpha-synuclein wreaks havoc on several fronts. It binds to mitochondria and impairs complex I, a critical step in energy production, leading to less available fuel for the cell and higher production of damaging reactive oxygen species.20PubMed. Alpha-synuclein mitochondrial interaction leads to irreversible translocation and complex I impairment Alpha-synuclein aggregates also interact with microglia, the brain’s immune cells, prompting them to mount an inflammatory response that becomes chronic over time and damages surrounding neurons rather than protecting them.21PubMed Central. The Interplay between α-Synuclein and Microglia in α-Synucleinopathies
Phosphorylation at Serine 129
In Parkinson’s brains, a huge proportion of the alpha-synuclein found in Lewy bodies carries a chemical modification: phosphorylation at a specific spot called serine 129. This phosphorylated form, often abbreviated pS129, has been widely used as a marker of disease. The assumption for years was that phosphorylation drives aggregation. Surprisingly, recent work suggests the opposite: phosphorylation at serine 129 actually inhibits fibril formation and reduces seeding, the ability of misfolded seeds to corrupt new copies of the protein. In cell-based assays, the phosphorylated form showed lower toxicity as well.22PubMed Central. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity This has raised the possibility that pS129 is not a villain but a late-arriving protective response, the brain’s attempt to cap aggregation after it has already begun.
In healthy neurons, phosphorylation at serine 129 appears to be a normal event driven by neuronal activity. When neurons fire, pS129 levels rise substantially within hours and accumulate at synaptic sites, suggesting it plays a physiological role in tuning synaptic function.23npj Parkinson’s Disease. Dynamic physiological α-synuclein S129 phosphorylation is driven by neuronal activity The clinical significance is real: if pS129 is protective, then designing drug trials that use reduced pS129 as a sign of success may be measuring the wrong thing.
Detecting Misfolded Alpha-Synuclein in Living Patients
One of the biggest clinical gaps in Parkinson’s disease has been the lack of a reliable biological test. Diagnosis still rests heavily on clinical assessment of symptoms. That is starting to change through two complementary approaches.
The first is a cerebrospinal fluid test called a seed amplification assay, which detects the seeding activity of misfolded alpha-synuclein. In one longitudinal study, this assay was positive in about 96% of people with confirmed Parkinson’s disease. It also identified cases of Lewy body co-pathology in patients diagnosed with a different condition, progressive supranuclear palsy, by detecting a distinctive low-level seeding pattern.24The Lancet Neurology. Diagnostic and prognostic value of quantitative α-synuclein seed amplification assay kinetic measures in Parkinson’s disease: a longitudinal cohort study
The second approach is a skin biopsy. Phosphorylated alpha-synuclein accumulates in the tiny nerve fibers within the skin, and it can be detected with a punch biopsy. In a large study, skin biopsies identified about 93% of Parkinson’s patients, 98% of those with multiple system atrophy, and 96% of those with dementia with Lewy bodies, with a false-positive rate of only about 3% among healthy controls.25JAMA. Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies When researchers focused specifically on deposits within nerve fibers rather than surrounding tissue, accuracy improved further, reaching 100% specificity for distinguishing early Parkinson’s from conditions it is commonly confused with, like essential tremor or vascular parkinsonism.26Brain. Skin intraneural phosphorylated α-synuclein is a highly specific biomarker for early Parkinson’s disease
Therapeutic Strategies Aimed at Alpha-Synuclein
If alpha-synuclein aggregation drives the disease, then clearing or blocking that aggregation should slow it down. That logic has produced two main therapeutic strategies, both still in development.
The most advanced is immunotherapy: antibodies designed to bind and neutralize alpha-synuclein in the spaces between neurons. Prasinezumab, a monoclonal antibody, reached phase 2 trials but did not hit its primary endpoint, meaning the treated group did not differ from placebo on the overall composite measure of disease progression.27PubMed Central. Future of Monoclonal Antibody Therapy in Parkinson’s Disease There were, however, signs that the drug slowed motor decline specifically, and post hoc analysis suggested the benefit was more apparent in patients whose disease was progressing rapidly.28Nature Medicine. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease Larger confirmatory trials are underway, focused on those rapidly progressing subgroups.29PubMed Central. An update on immune-based alpha-synuclein trials in Parkinson’s disease
The second strategy is reducing alpha-synuclein production at the source using antisense oligonucleotides (ASOs), short synthetic molecules that block the messenger RNA for the SNCA gene so less protein gets made. In mouse models of Parkinson’s, ASOs delivered into the brain successfully reduced alpha-synuclein levels and improved neurological function.30Scientific Reports. Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease A newer approach packages the ASO inside tiny membrane-bound bubbles called exosomes, which neurons absorb more readily, improving delivery and reducing toxicity. In mice carrying a Parkinson’s-causing SNCA mutation, this exosome-delivered ASO decreased alpha-synuclein aggregation, protected dopamine neurons, and improved movement.31PubMed. Exosome-mediated delivery of antisense oligonucleotides targeting α-synuclein ameliorates the pathology in a mouse model of Parkinson’s disease These results are encouraging but remain preclinical. Getting ASOs into the human brain safely and in sufficient quantity is a substantial hurdle that has not yet been cleared for this disease.
Different Strains for Different Diseases
Alpha-synuclein aggregation is not exclusive to Parkinson’s. It drives a family of conditions called synucleinopathies, which also includes multiple system atrophy (MSA) and dementia with Lewy bodies (DLB). These diseases look quite different clinically: MSA attacks the brain’s coordination and autonomic systems, while DLB features visual hallucinations and fluctuating cognition alongside parkinsonism.
A growing body of evidence suggests these clinical differences may trace back to structurally distinct “strains” of misfolded alpha-synuclein, analogous to how different prion strains cause different patterns of damage. When researchers amplified alpha-synuclein fibrils from the brains of people who had died of Parkinson’s, MSA, or DLB and injected them into rat brains, the resulting pathology mirrored the disease of origin: each strain produced a characteristic pattern of spread and cell damage.32PubMed Central. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies Studies in human dopamine neurons have confirmed that Parkinson’s-derived and MSA-derived alpha-synuclein seeds produce distinct patterns of toxicity and aggregation, consistent with the strain hypothesis.33Nature Communications. Phenotypic manifestation of α-synuclein strains derived from Parkinson’s disease and multiple system atrophy in human dopaminergic neurons
The strain concept also has diagnostic implications. The seed amplification assay mentioned earlier can distinguish Parkinson’s from MSA based on differences in how fast and how much seeding occurs, offering a potential way to tell these conditions apart in life rather than only at autopsy.
Cross-Seeding with Tau
Parkinson’s disease often coexists with Alzheimer’s pathology, and many late-stage Parkinson’s patients develop tau tangles alongside their Lewy bodies. This overlap is not just a coincidence of aging brains. In laboratory settings, alpha-synuclein and tau can directly cross-seed each other, meaning misfolded alpha-synuclein promotes tau aggregation and vice versa.34PubMed Central. Strain-Distinct α-Synuclein and Tau Cross-Seeding Uncovered by Correlative Approach with Optical Photothermal Infrared Sub-Micron Imaging In animal models, mixed alpha-synuclein and tau aggregates were more efficient at seeding tau pathology than either protein alone, though the reverse was not true: the mixed aggregates did not enhance alpha-synuclein pathology.35PubMed Central. Differential cross-seeding properties of tau and α-synuclein in mouse models of tauopathy and synucleinopathy This asymmetry raises the possibility that alpha-synuclein pathology may help drive the cognitive decline seen in Parkinson’s by accelerating tau-related damage in brain regions responsible for memory and thinking.
Beta-Synuclein as a Natural Counterweight
Alpha-synuclein has a close relative in the brain called beta-synuclein. The two proteins sit side by side at synapses, and beta-synuclein appears to act as a natural brake on alpha-synuclein aggregation.36PubMed Central. Multi-Pronged Interactions Underlie Inhibition of α-Synuclein Aggregation by β-Synuclein Structural studies have shown that the two form brief, specific pairings in a head-to-tail arrangement. These fleeting interactions are enough to disrupt the more disordered self-to-self contacts that alpha-synuclein uses to begin clumping.37PubMed Central. Unveiling transient protein-protein interactions that modulate inhibition of alpha-synuclein aggregation by beta-synuclein, a pre-synaptic protein that co-localizes with alpha-synuclein Whether boosting beta-synuclein levels or mimicking its interaction with alpha-synuclein could have therapeutic value is an open question, but the finding underscores that the brain has its own defense mechanisms against aggregation, and Parkinson’s may represent a situation in which those defenses are overwhelmed.